A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DF / desferrioxamine

[Related PubMed/MEDLINE]
Total Number of Papers: 121
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DF  (>> Co-occurring Abbreviation)
Long Form:   desferrioxamine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. CDR, GPC3, HCC, NSG, PDX, ROI
2018 ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. MM, WB
2018 Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. BV, PET
2017 CD38 as a PET Imaging Target in Lung Cancer. ---
2016 Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging. PET, uPA
2016 CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. HCC, NIRF, PET, s.c
2016 Deferoxamine improves antioxidative protection in the brain of neonatal rats: The role of anoxia and body temperature. ---
2016 Deferoxamine prevents cerebral glutathione and vitamin E depletions in asphyxiated neonatal rats: role of body temperature. ---
2016 ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors. mAb
10  2015 Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in beta-Thalassemic Mice. ---
11  2015 The Effects of Medicago Sativa and Allium Porrum on Iron Overload in Rats. SI, TIBC
12  2015 ⁸⁹Zr-Labeled Versus ⁴I-Labeled alphaHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo. ---
13  2014 Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model. SM
14  2014 Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression. Ga-68, HER2, PET, scFv
15  2014 Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography. huCD20TM, NHL, PET
16  2013 Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats. BUN, Cr, KID, SM
17  2012 Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. ---
18  2010 Iron chelation prevents lung injury after major hepatectomy. PAF-AcH, SOD
19  2010 Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Df-Chx-Mal, Df-Iac, PET
20  2009 Comparative mutagenic effects of structurally similar flavonoids quercetin and taxifolin on tester strains Salmonella typhimurium TA102 and Escherichia coli WP-2 uvrA. CAT, EDTA, NGS, QT, SOD, TF
21  2007 Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy. SI/TIBC
22  2007 Topical applications of iron chelators in photosensitization. DMSA, EDTA, PpIX, ROS, UV
23  2006 Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. MRI, TM
24  2005 Deferoxamine photosensitizes cancer cells in vitro. ALA, PpIX
25  2005 Effect of neonatal body temperature on postanoxic, potentially neurotoxic iron accumulation in the rat brain. ---
26  2005 Myeloperoxidase activity imaging using (67)Ga labeled substrate. CT, DCC, MPO, SPECT
27  2004 Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum. AD, AS, FG
28  2002 Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and requires iron. DCs, GM-CSF
29  2002 Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. EMSA, HIV-1, NF, PBL
30  2002 Melatonin improves deferoxamine antioxidant activity in protecting against lipid peroxidation caused by hydrogen peroxide in rat brain homogenates. 4-HDA, MDA
31  2002 Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. ---
32  2001 A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. CDKI
33  2001 Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. PMA
34  2000 Effect of Desferrioxamine on Silica-Induced Pulmonary Reaction. IL-8, MDA, TNF-alpha
35  2000 Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice. CHO, MDA, MLT, STZ, TG
36  2000 Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ---
37  1999 Hemoglobin toxicity in experimental bacterial peritonitis is due to production of reactive oxygen species. DMPO, Hb
38  1999 Long-term follow-up of skeletal dysplasia in thalassaemia major. TM
39  1999 Noninvasive evaluation of in vivo free radical reactions catalyzed by iron using in vivo ESR spectroscopy. ESR
40  1998 Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. ---
41  1998 Role of H2O2 and heme-containing O2 sensors in hypoxic regulation of tyrosine hydroxylase gene expression. DCF, TH
42  1997 An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients. ---
43  1997 Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. DTPA
44  1997 Flow cytometric assessment of hydroxypyridinone iron chelators on in vitro growth of drug-resistant malaria. FCM, MIC
45  1997 IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture. DRBCs, RE
46  1996 Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. ALDA, HIF-1, PGK-1, VEGF
47  1996 Applicability of short-lived radiometallic nuclide for high sensitivity two-site "sandwich" immunoradiometric assay: human growth hormone assay. 67Ga, hGH, SA
48  1996 Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging. ---
49  1995 Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. ALA, BCCs, PDT
50  1995 Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures. ---
51  1994 Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. ---
52  1994 Deferoxamine given at reperfusion improves function of the cold-stored rat heart. KHB
53  1994 Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. ---
54  1994 Effect of long-term removal of iron from asbestos by desferrioxamine B on subsequent mobilization by other chelators and induction of DNA single-strand breaks. SSBs
55  1994 Free radical modes of cytotoxicity of adriamycin and streptonigrin. ADR, dsb, STN, TP
56  1994 Regulation of protein kinase C (PKC) expression by iron: effect of different iron compounds on PKC-beta and PKC-alpha gene expression and role of the 5'-flanking region of the PKC-beta gene in the response to ferric transferrin. FAC, FeLF, FeTF, PKC
57  1993 Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. LDH, MDA
58  1993 Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. DTPA
59  1993 Desferrioxamine and urinary zinc excretion in beta-thalassemia major. ---
60  1993 Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. ---
61  1993 Lethal photosensitization by endogenous porphyrins of PAM cells--modification by desferrioxamine. ALA
62  1993 Possible involvement of active oxygen species in selenite toxicity in isolated rat hepatocytes. DFMn, LDH, SOD, TBA-RS
63  1993 Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. ---
64  1993 Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. HBT
65  1992 Allylamine toxicity in embryonic myocardial myocyte reaggregate cultures: The role of extracellular metabolism by benzylamine oxidase. AA, ACR, BZO, MESNA, MMR
66  1992 Deferoxamine effect on selenite-induced cataract formation in rats. PSC
67  1992 Effect of iron chelators on paraquat toxicity in rats and alveolar type II cells. CP51
68  1992 Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function. Con A, CP, IL-2
69  1992 Gallium-labeled deferoxamine-galactosyl-neoglycoalbumin: a radiopharmaceutical for regional measurement of hepatic receptor biochemistry. DF-NGA, NGA
70  1992 Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. RE
71  1992 The antimalarial effect of iron chelators: studies in animal models and in humans with mild falciparum malaria. ---
72  1991 Ferrioxamine B derivatives as hepatobiliary contrast agents for magnetic resonance imaging. MRI
73  1991 Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. ADP
74  1990 Iron chelation. ---
75  1990 Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning". PBN
76  1990 L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. UIE
77  1990 Mechanism of protection of alveolar type II cells against paraquat-induced cytotoxicity by deferoxamine. PBH
78  1990 Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro. ---
79  1990 Stress initiated during isolation of rat renal proximal tubules limits in vitro survival. LDHR, TBA
80  1989 Continuous intravenous infusion of deferoxamine reduces mortality by paraquat in vitamin E-deficient rats. ---
81  1988 Antioxidant capacity of desferrioxamine and ferrioxamine in the chemically-initiated lipid peroxidation of rat erythrocyte ghost membranes. ---
82  1988 Deferoxamine inhibition of malaria is independent of host iron status. ---
83  1988 Deferoxamine-induced growth retardation in patients with thalassemia major. ---
84  1988 Expression of the haemopexin-transport system in cultured mouse hepatoma cells. Links between haemopexin and iron metabolism. Hepa, MHBP
85  1988 Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin. ara-C
86  1988 Iron-chelating therapy. ---
87  1987 Antioxidant capacity of desferrioxamine in biological systems. ---
88  1987 Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. ---
89  1987 [Evaluation of deferoxamine capacity to revert a severe porphyria induced by hexachlorobenzene]. HCB
90  1986 Desferoxamine blocks IL 2 receptor expression on human T lymphocytes. MNC
91  1986 Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria. ALA-S, HCB, PCL, PCL
92  1986 Non-ferritin, non-heme iron pools in rat tissues. LMW
93  1985 Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. ---
94  1985 Failure of desferrioxamine to modify the toxicity of paraquat in rats. ---
95  1985 In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ---
96  1985 Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent. ---
97  1984 Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis. IH, UIE
98  1983 Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration. HBED
99  1983 Syntheses of iron bis(pyridoxal isonicotinoylhydrazone)s and the in vivo iron-removal properties of some pyridoxal derivatives. PINH
100  1983 [Inhibition of heme biosynthesis in erythroid precursors (BFU-e) isolated from human peripheral blood: effects on globin synthesis]. ---